​

Korsana Biosciences Stock (NASDAQ:KRSA)

RevenueFinancialsChart
Korsana Biosciences by TradingView

Previous Close

$30.22

52W Range

$7.19 - $59.36

50D Avg

$31.09

200D Avg

$21.95

Market Cap

$141.10M

Avg Vol (3M)

$71.30K

Beta

1.73

Div Yield

-

KRSA Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

19

IPO Date

Sep 09, 2026

Website

KRSA Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24
License Agreement$1.75M
License$250.00K

Fiscal year ends in Dec 25 | Currency in USD

KRSA Financial Summary

Dec 25Dec 24Dec 23
Revenue$2.07M$2.00M-
Operating Income$-4.97M$-3.63M$-12.95M
Net Income$-3.53M$-3.06M$-5.26M
EBITDA$-3.53M$-3.06M$-9.58M
Basic EPS$-7.63$-8.47$-62.93
Diluted EPS$-7.63$-8.47$-62.93

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
XTLBXTL Biopharmaceuticals Ltd.
TCRTAlaunos Therapeutics, Inc.
ADXNAddex Therapeutics Ltd
RADXRadiopharm Theranostics Limited
KTTAPasithea Therapeutics Corp.
PLRZPolyrizon Ltd.
QNRXQuoin Pharmaceuticals, Ltd.